-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Amgen, Inc (AMGN) – Amgen Stock Is a Powerhouse
Biotechs such as Amgen stock have been riding high for more than a month. AMGN in particular looks promising for new money.
Novavax, Inc.: NVAX Stock Gets Gutted — Can It Still Double?
Novavax, Inc. (NASDAQ:NVAX) is leading the biotech charge downward today on dismal earnings that left investors questioning the bull case.
How UnitedHealth Group Inc Ranks As a Top 15 Analyst Pick (UNH)
A study of analyst recommendations at the major brokerages shows that UnitedHealth Group is the #1 pick in the Dow
The iShares Nasdaq Biotechnology Index (ETF) (IBB) — It’s Make-or-Break Time
While the intermediate-term trend remains intact for the IBB etf, earnings season for large biotech companies could be make-or-break.
The iShares Nasdaq Biotechnology Index (ETF) (IBB): Gravity Calls!
Active investors and traders should look to play the iShares Nasdaq Biotechnology Index (ETF) (IBB) to the short side until the picture changes.
ABBV Stock: Could AbbVie Inc’s Gamble on Stemcentrx Pay Off?
Stemcentrx's acquisition does little to alleviate the risk of the potential decrease in sales once Humira loses patent protection.
Is Pfizer Inc. Finally Safe To Buy Again? (PFE)
A first-quarter earnings and revenue beat has investors excited once again with formerly beat-down Pfizer Inc. Is now the time to buy PFE?
Omega Healthcare Investors Inc: A High-Yield Healthcare REIT (OHI)
Omega Healthcare Investors is a real estate investment trust with a high dividend yield but with a mixed history. Is OHI a long-term dividend winner?
5 Dividend Stocks Starting a Multi-Decade Bull Market
A 'niche" bull run is in the market that's going to continue for the long term. Healthcare stocks are solid long-term portfolio dividend stocks to buy
iShares Nasdaq Biotechnology Index (ETF) (IBB): Nibble on the Long Side
Biotech stocks, after some prolonged weakness, are starting to show promising relative and absolute strength. That means opportunity in the IBB.
Trade of the Day: Nautilus, Inc. (NYSE:NLS)
Nautilus (NLS) shares fell 3.7% Monday on no news, offering traders a phenomenal entry point.
Opko Health Inc.: FDA Denial Won’t Kill OPK
The approval delay of Rayaldee, Opko Health's new billion-dollar drug, won't hurt its market performance. OPK is a high-risk/high-reward stock.
Gilead Sciences, Inc.: GILD Could Squeeze the Bears From Here
Gilead Sciences enjoyed a rally Monday along with the rest of the biotech sector. This breakout could be followed up by a short squeeze in GILD stock.
3 Healthcare Dividend Stocks With 200% Upside
Worried about President Trump? The Fed? If so, here's some simple advice: ignore it all, and invest in these stocks in the healthcare sector.
The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is a Buy, But Not for Long
The iShares Nasdaq Biotechnology ETF (IBB) has yet to pull off something that other parts of the market have -- and that spells opportunity in IBB.
2 Drug Stocks To Buy For Safe Dividends And 20% Gains
With all the talk on the campaign trail about drug costs, it's safe to say the pharmaceutical industry is under siege. But these drug stocks are solid buys
